Humedix

200670· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩25,050+0.00%

2026-09-18

Financials

Valuation Metrics

Humedix's Market Cap is ₩2813B. At end of 2025 it was ₩4531B. Ranked #689 of 2,421 in KR market (top 28%), #289 of 1,640 on KOSDAQ (top 18%), #75 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 32%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	281.31B KRW	KR#689/2,421 Sec#75/231
Revenue	177.88B KRW	KR#1,094/2,421 Sec#65/231
Net Income	45.91B KRW	KR#443/2,421 Sec#27/231
Total Assets	323.64B KRW	KR#995/2,421 Sec#62/231
Net Assets	299.59B KRW	KR#718/2,421 Sec#47/231
Employees	371	KR#650/2,421 Sec#57/231
Value
P/E	6.13x	KR#468/2,421 Sec#21/231
P/B	0.94x	KR#1,407/2,421 Sec#88/231
PEG	0.38x	KR#658/2,421 Sec#41/231
P/S	1.58x	KR#1,669/2,421 Sec#96/231
EV/EBITDA	5.93x	KR#301/2,421 Sec#8/231
FCF Yield	13.23%	KR#492/2,421 Sec#15/231
Profitability
ROE	15.32%	KR#310/2,421 Sec#19/231
ROA	14.19%	KR#132/2,421 Sec#10/231
Op. Margin	22.88%	KR#116/2,421 Sec#15/231
Revenue Growth	12.61%	KR#780/2,421 Sec#77/231
Earnings Growth	16.33%	KR#716/2,421 Sec#48/231
Financial Health
Debt Ratio	8.03%	KR#92/2,421 Sec#19/231
Total Debt	0 KRW	KR—/2,421 Sec—/231
FCF	37.21B KRW	KR#356/2,421 Sec#21/231
Cash	39.88B KRW	KR#854/2,421 Sec#53/231
Net Debt/EBITDA	-0.98x	KR#388/2,421 Sec#21/231
Dividend
Div. Yield	3.71%	KR#475/2,421 Sec#19/231
Div. Growth	46.03%	KR#268/2,421 Sec#10/231
Performance
1Y Return	-61.40%	KR#2,216/2,421 Sec#208/231
1M Return	-1.96%	KR#1,465/2,421 Sec#116/231
From 52W High	-65.40%	KR#2,047/2,421 Sec#168/231
1Y MDD	-67.39%	KR#1,855/2,421 Sec#154/231
Trading
Volume	9,630 shares	KR#1,929/2,421 Sec#188/231
Trading Value	240.1M KRW	KR#1,204/2,421 Sec#123/231
Foreign Own.	6.59%	KR#676/2,421 Sec#59/231
Per Share
EPS	4,088 KRW	KR#257/2,421 Sec#16/231
BPS	26,678 KRW	KR#427/2,421 Sec#30/231

Company Info

CEO 강민종

Employees 371

Founded 2003

HQ 경기도 성남시, KR

Website www.humedix.com

Humedix, established in 2003 for the manufacturing and sale of functional foods, changed its name from its original in 2010 and was listed on KOSDAQ in 2014. Through research and development of hyaluronic acid and PDRN, the company produces and supplies fillers, botulinum toxin, arthritis therapeutics, and cosmetics to domestic and international healthcare markets. Humedix strengthens its market presence by acquiring European CE and Chinese NMPA certifications for its proprietary HI method fillers. It maximizes synergy through heparin sodium localization and an aesthetic solution portfolio, and is headquartered in Seongnam-si, Gyeonggi-do.